or Try an Advanced Search...

    Technical Analysis for STOK - Stoke Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 9.49 9.33% 0.81
    STOK closed up 9.33 percent on Wednesday, January 15, 2025, on 1.93 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical STOK trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Slingshot Bearish Bearish Swing Setup 9.33%
    Stochastic Buy Signal Bullish 9.33%
    Calm After Storm Range Contraction 9.33%
    Lower Bollinger Band Walk Weakness 9.33%
    Outside Day Range Expansion 9.33%
    Older End-of-Day Signals for STOK ...

       Recent Intraday Alerts

    Alert Time
    Up 10% about 7 hours ago
    Up 1 ATR about 9 hours ago
    2x Volume Pace about 10 hours ago
    3x Volume Pace about 10 hours ago
    Rose Above Previous Day's High about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    STOK Chart by TradingView

    Profile

    Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50 percent of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke was launched with investments by Apple Tree Partners. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Disease Precision Medicine Genetic Diseases Proteins Epigenetics Severe Genetic Diseases

    Is STOK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jan 8 Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    Jan 8 Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
    Jan 7 Stoke Therapeutics to initiate late-stage study for the treatment of Dravet syndrome
    Jan 7 Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
    Jan 6 Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome
    Dec 26 The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
    Dec 24 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
    Dec 17 Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth
    Dec 6 Stoke Therapeutics Reports Durable Seizure Control With Zorevunersen in Dravet Patient
    Dec 6 Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome
    See more STOK news...

    Comments

    Indicators

    Indicator Value
    52 Week High 17.58
    52 Week Low 4.09
    Average Volume 726,644
    200-Day Moving Average 13.16
    50-Day Moving Average 11.84
    20-Day Moving Average 10.68
    10-Day Moving Average 9.92
    Average True Range 0.76
    RSI (14) 37.11
    ADX 21.54
    +DI 18.79
    -DI 29.60
    Chandelier Exit (Long, 3 ATRs) 10.95
    Chandelier Exit (Short, 3 ATRs) 10.71
    Upper Bollinger Bands 12.93
    Lower Bollinger Band 8.44
    Percent B (%b) 0.23
    BandWidth 42.02
    MACD Line -0.83
    MACD Signal Line -0.64
    MACD Histogram -0.1858
    Fundamentals Value
    Market Cap 423.76 Million
    Num Shares 44.7 Million
    EPS -2.43
    Price-to-Earnings (P/E) Ratio -3.91
    Price-to-Sales 22.55
    Price-to-Book 1.21
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.93
    Resistance 3 (R3) 10.86 10.32 10.69
    Resistance 2 (R2) 10.32 9.95 10.35 10.61
    Resistance 1 (R1) 9.90 9.72 10.11 9.97 10.53
    Pivot Point 9.36 9.36 9.46 9.39 9.36
    Support 1 (S1) 8.94 8.99 9.15 9.01 8.45
    Support 2 (S2) 8.40 8.76 8.43 8.37
    Support 3 (S3) 7.99 8.40 8.29
    Support 4 (S4) 8.05